CURE ETF

After recently taking profit in the CURE ETF, we again add the name back onto our watchlist and identify the range where we expect buying support to rebuild.

Buy $58.50 target.

You’re not a member!  Trial today

Separate to the above opportunity, we see upside in the large-cap biotech stocks in the US. In particular, we like Abbvie, Biogen, Gilead, Johnson & Johnson, Merk, and Pfizer.

If you’d like to discuss setting up a US broking account with Investor Signals, please call me on 1300 614 002.

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.